“Gorlin Syndrome Beyond PTCH1 and SUFU: Leave No Patients Undiagnosed”
Barbara Rivera Polo, PhD
We are thrilled to announce the recipient of the 2025 GSA Research Grant Award is Barbara Rivera, PhD, Principal Investigator and Miguel Servet Fellow at the Rare Tumors Lab – Hereditary Cancer Programme with the Bellvitge Biomedical Research Institute (IDIBELL). Congratulations, Dr. Rivera Polo!
Dr. Rivera Polo's proposal, “Gorlin Syndrome Beyond PTCH1 and SUFU: Leave No Patients Undiagnosed,” received the highest scores from both our Medical and Scientific Advisory Committee (MSAC) and our first-ever Community Grant Review Committee. Her research will pursue discovery of factors contributing to a clinical diagnosis of Gorlin syndrome in cases where the known genetic mutations are not present.
2024
“Defining the BCC microenvironment change in response to smoothened inhibition: Identification of a role for addition of checkpoint inhibitor to optimize antitumor therapy for overwhelming disease.”
Dr. John Carucci, NYU Grossman School of Medicine.
2023
“Clinical Practice Guidelines for the Management of Basal Cell Carcinoma in Gorlin Syndrome.”
Murad Alam, MD, Northwestern University Feinberg School of Medicine
Co-Investigator:Dr. Cahn, PGY-3 Resident in the Department of Dermatology, University of Illinois, Chicago.
.jpg?width=200&height=200&name=1578553822%20(1).jpg "1578553822 (1)")
%20(2).png?width=150&height=64&name=GSA%20Logo%20High%20Res%20No%20Background%20(1)%20(2).png)
%20(2)-1.png?width=200&height=85&name=GSA%20Logo%20High%20Res%20No%20Background%20(1)%20(2)-1.png)